Before sharing sensitive information, make sure you're on a federal government site. All providers must complete the enrollment in the Provider Enrollment Portal, after which they are then able to log vaccine administrations in their chosen Vaccine Reporting System. The VIS barcode does not contain any data that is not currently on the VIS, and there is no requirement that immunizers supply VIS data to IIS. State Government websites value user privacy. The interval between doses is determined by the childs age at the start of the vaccination series. Page 9 of the Controlant Onsite Temperature Monitoring Playbook for Sites provides step-by-step instructions for performing this task. Summary (Cont.) The grey caps and a grey label border have improved stability with a change in buffer and are the only vials that do not require dilution to make handling and administration easier. On this date, Pfizer-BioNTech Comirnatytransitioned to an authorization under theFood and Drug Regulations. Download AMA Connect app for This table is also available on the CDC Public Health Information Network (PHIN) Vocabulary Access and Distribution System (VADS) website. Saving Lives, Protecting People, COVID-19 Vaccine Breakthrough Case Investigation and Reporting, Clinical Decision Support for Immunization (CDSi), COVID-19 Vaccine Lot Number and Expiration Date Tool, National Center for Immunization and Respiratory Diseases, Use of COVID-19 Vaccines in the U.S.: Appendices, FAQs for the Interim Clinical Considerations, Myocarditis and Pericarditis Considerations, Jurisdictions: Vaccinating Older Adults and People with Disabilities, Vaccination Sites: Vaccinating Older Adults and People with Disabilities, Vaccinating Patients upon Discharge from Hospitals, Emergency Departments & Urgent Care Facilities, Vaccines for Children Program vs. CDC COVID-19 Vaccination Program, FAQs for Private & Public Healthcare Providers, Talking with Patients about COVID-19 Vaccination, Talking to Patients with Intellectual and Developmental Disabilities, How to Tailor COVID-19 Information to Your Audience, How to Address COVID-19 Vaccine Misinformation, Ways to Help Increase COVID-19 Vaccinations, COVID-19 Vaccination Program Operational Guidance, What to Consider When Planning to Operate a COVID-19 Vaccine Clinic, Using the COVID-Vac Tool to Assess COVID-19 Vaccine Clinic Staffing & Operations Needs, Connecting with Federal Pharmacy Partners, Resources to Promote the COVID-19 Vaccine for Children & Teens, COVID-19 Vaccine Access in Long-term Care Settings, Information for Long-term Care Administrators & Managers, Vaccinating Dialysis Patients and Healthcare Personnel, What Public Health Jurisdictions and Dialysis Partners Need to Know, Supporting Jurisdictions in Enrolling Healthcare Providers, Vaccine Administration Management System (VAMS), Resources for Jurisdictions, Clinics, and Organizations, 12 COVID-19 Vaccination Strategies for Your Community, How to Engage the Arts to Build COVID-19 Vaccine Confidence, Strategies for Reaching People with Limited Access to COVID-19 Vaccines, U.S. Department of Health & Human Services. The ancillary kits are supplied to support this guidance. Storage of the vials between -96C to -60C (-141F to -76F) is not considered an excursion from the recommended storage condition. Pfizer-BioNTech Comirnaty Original and Omicron BA.1, bivalent COVID-19 vaccine. Sites that don't are often hospitals or other larger systems. Such vaccines have a dynamic expiration date, which can change over time as additional stability data become available. If an ultra-low temperature freezer is not available, the thermal container in which the Purple Cap Pfizer-BioNTech COVID-19 vaccine arrives may be used as temporary storage when consistently re-filled to the top of the container with dry ice. If the sixth dose is not obtained, you will need to report this dose as wasted in WIR. The mRNA sequence from the Pfizer-BioNTech Comirnaty COVID-19 vaccine is also included in the Pfizer-BioNTech Comirnaty Original and Omicron BA.4/BA.5, bivalent COVID-19 vaccine. Questions regarding this table should be directed to the IIS Technical Assistance Team (or use IIS mailing address). Once the data is received at the Control Tower, a quality disposition report is created which documents quality considerations and identifies any suspected nonconforming items. Cookies used to make website functionality more relevant to you. *Cartons of Pfizer-BioNTech COVID-19 Vaccine vials may also arrive at refrigerator temperature 2C to 8C. Presentation . Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. <>/Metadata 131 0 R/ViewerPreferences 132 0 R>> 4 0 obj Ensure the ID on the card matches a driver's license, then check for appropriate dose intervals. The dosing for 6 months to less than 5 years is a 3-dose primary series of 3 micrograms each of the vaccine. Providers are responsible for adhering to all requirements outlined in the agreement. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests. One dose (0.2 mL) contains 3 micrograms of COVID-19 mRNA vaccine. Please keep in mind this guidance does not replace the need to use the correct needle size for intramuscular (IM) injection based on the individual. Pfizer Statement: "Pfizer received inital FDA BLA license on 8/23/2021 for its COVID-19 vaccine for use in individuals 16 and older (COMIRNATY). The .gov means its official.Federal government websites often end in .gov or .mil. These decisions are based on public health recommendations and the latest evidence. Before sharing sensitive information, make sure you're on a federal government site. Organization Type Other (Describe) The new files include COVID-19 vaccine National Drug Codes (NDCs), lot numbers, and lot expiration dates. 3 0 obj iPhone or This is the same process that is used to order all COVID-19 vaccines. Based on your planned use, please let us know . Manually upload the temperature monitoring data onto the computer. Its safety and effectiveness in younger people has not yet been established. Which dose is being administered? Explore trends in COVID-19 vaccine confidence in the U.S. We take your privacy seriously. To stay informed about the latest news from the CDC, guides, clinical information, and more visit the COVID-19 vaccine development section. Information and resources to help public health departments and laboratories investigate and report COVID-19 vaccine breakthrough cases. The lot number you entered (AB0000) does not exist. The vaccine has been known as the Pfizer-BioNTech COVID-19 vaccine and can be marketed as COMIRNATY (koe-mir-na-tee), for the prevention of COVID-19 disease in individuals 12 years of age and older. Official website of the State of Wisconsin. Contact CBERSPL@FDA.HHS.GOV to advise FDA of your intent to begin submitting LDD Reports electronically. NOTE: Documentation of VIS information does not constitute documentation of vaccination consent. endstream endobj 126 0 obj <. Please enter another Lot # or contact Pfizer Customer Service at 8006667248 , option 8 OR [email protected] . Clinical trials showed that beginning 1 week after the second dose, the Pfizer-BioNTech Comirnaty COVID vaccine was about: Effectiveness data supporting the authorization in children ages 6 months to under 5 years are based on a comparison of immune responses in this age group to individuals ages 16 to 25 years. Featured . Peds (5-11) has a 6-month expiration if held frozen at ULT oMFG date + 6 months = expiration date oThis includes the month of manufacturee.g., 8/2021 includes August. Log in. Monovalent mRNA COVID-19 vaccines are no longer authorized for emergency use in the United States. The Pfizer-BioNTech Comirnaty Original and Omicron BA.4/BA.5, bivalent COVID-19 vaccine is approved as a booster for people who are 5 years of age and older. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. Do not administer the vaccine to people with a known history of a severe allergic reaction (for example, anaphylaxis) to any ingredient of the Pfizer-BioNTech COVID-19 vaccine. Tracking COVID-19 vaccine distribution and administration activities requires collaboration between public and private information technology (IT) systems and integration of existing and newly developed IT systems. CDC has added two-dimensional (2D) data matrix barcodes to Vaccine Information Statements (VIS). Providers giving off-label doses would be in violation of the CDC Program provider agreement, potentially impacting their ability to remain a provider in the CDC program. Vaccinators can place orders for Pfizer SDVs by completing the COVID-19 Vaccine Ordering Survey. 1 0 obj They help us to know which pages are the most and least popular and see how visitors move around the site. CDCs COVID-19 Vaccine Expiration Date Tracking Tool can help providers keep track of the expiration date by lot number. Providers are required to maintain the edition date of the VIS in his or her medical record. Please contact CDER Drug Shortage Staff at drugshortages@fda.hhs.gov with questions regarding this table. Fraudulent cards can be reported to your state attorney general's office or online to the Department of Health and Human Services. A Quality Report should be provided via email within one to three hours. No Pfizer vaccine is authorized as a booster dose for this age group. To learn more, view our full privacy policy. endobj It would violate the provider agreement and could expose providers to the following risks: Onsite temperature monitoring for Pfizer vaccines (after product acceptance) ended on November 28, 2022. This is known as a mixed vaccine series. You must keep all logs for threeyears per the COVID-19 Vaccination Program Provider Agreement. Pfizer-BioNTech COVID-19 Vaccine Expiration Date Extension and Beyond-Use Date Recently the Food and Drug Administration (FDA) extended the expiration date for Pfizer-BioNTech COVID-19 Vaccine (monovalent and bivalent) from 12 to 18 . However, review of the specific elements of the card can help you assess for evidence of fraud. Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data. Please follow these steps to begin submitting LDD Reports electronically: Step 1 Raleigh, NC 27699-2000. V-safeis asmartphone-basedtoolthatuses text messaging and web surveysto provide personalized health check-ins aftersomeonereceivesa COVID-19 vaccination. You will be subject to the destination website's privacy policy when you follow the link. All Dosing: Refer . Katherine Ellen Foley. The second field is the edition date of the VIS. Lot Numbers Aggregate Vaccine Counts Search/Add Search Results Detail Correct Decrementing Orders[Transfers endstream endobj startxref One dose (0.3 mL) contains 30 micrograms of COVID-19 mRNA vaccine, Vials with a grey cap and grey label border contain 6 doses of 0.3 mL (, Vials with an orange cap and orange label border contain 10 doses of 0.2 mL after dilution. The Stop Shipment button does not deactivate monitoring. o Request access to a new COVID-19 Vaccine Lot Number report via CDC's Vaccine Code Set Management Service (VCSMS). Providers and patients that have the lot numbers in stock will be able to use them through the corresponding new use dates to help with supply. Moderna COVID-19 Vaccine Packaging . Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985. Official websites use .gov Pfizer does not have an expiration date look -up tool. For assistance with CBER LDD submissions, contact CBERSPL@FDA.HHS.GOV. Submit a test file using FDA Test environment (provide link to the documentation you have for conducting pilot test). The only way to deactivate monitoring in the old DDL is through the email you receive from Controlant. Pfizer and Moderna are two-dose vaccines, while J&J is one dose.2) The lot number and expiration dateThe lot number is a string of numbers and letters that tracks this specific batch of vaccine . Vaccinators are encouraged to use SDVs at sites where they can increase access and availability of the bivalent booster vaccine. If you have questions, please reach out to your regional manager. The date printed on the Pfizer (maroon cap, orange cap, and gray cap) vaccine vials indicate the manufacture date and not the expiration date. CDC twenty four seven. Register as a new user. Instructions for updating the changing expiration dates in WIR start at minute 20:10. CDC INFORMATION. This technology is designed primarily to help immunization providers record information about the VIS as is required by the National Childhood Vaccine Injury Act (NCVIA). The following resources are also available on the above webpages: Contact McKesson MedSurg to reportEmail: snssupport@mckesson.com, Health care personnel or health departments in the U.S. can request a consultation fromThe Clinical Immunization Safety Assessment COVIDvax project websitePhone: 800-CDC-INFO (800-232-4636), COVID-19: Vaccinator Guidance for Pfizer Vaccine, Protecting and promoting the health and safety of the people of Wisconsin, American Rescue Plan Act Funding for Wisconsin, Governor Evers' Proposed 2023-2025 Budget, Statutory Boards, Committees and Councils, PRAMS (Pregnancy Risk Assessment Monitoring System), WISH (Wisconsin Interactive Statistics on Health) Query System, Find a Health Care Facility or Care Provider, Health Insurance Portability and Accountability Act (HIPAA), Long-Term Care Insurance Partnership (LTCIP), Psychosis, First Episode and Coordinated Specialty Care, Services for Children with Delays or Disabilities, Supplemental Security Income-Related Medicaid, Aging and Disability Resource Centers (ADRCs), Services for People with Developmental/Intellectual Disabilities, Services for People with Physical Disabilities, Nutrition, Physical Activity and Obesity Program, Real Talks: How WI changes the conversation on substance use, Small Talks: How WI prevents underage drinking, Health Emergency Preparedness and Response, Home and Community-Based Services Waivers, Medicaid Promoting Interoperability Program, Preadmission Screening and Resident Review, Alcohol and Other Drug Abuse (AODA) Treatment Programs, Environmental Certification, Licenses, and Permits, Health and Medical Care Licensing and Certification, Residential and Community-Based Care Licensing and Certification, stored in either a refrigerator or ultra-cold freezer, ingredient of the Pfizer-BioNTech COVID-19 vaccine, Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine, Emergency Use Authorization Fact Sheet for Recipients and Caregivers, Pfizer Vaccine Formulation/Presentation Guide, Pfizer-BioNTech COVID-19 Vaccine Expiry Tool, CDC's Vaccine Lot Number and Expiration Date webpage, Administration Overview for Pfizer-BioNTech COVID-19 Vaccine, Pfizer emergency use authorization fact sheet for people ages 12 years and older, COVID-19: General Guidance for Vaccinators page, https://www.pfizermedicalinformation.com/en-us/medical-updates, Food and Drug Administration (FDA) approved, CDC's webpage Pfizer-BioNTech COVID-19 Vaccine Overview and Safety, Comirnaty and Pfizer-BioNTech COVID-19 vaccine webpage, Advisory Committee on Immunization Practices, Comirnaty and Pfizer-BioNTech COVID-19 Vaccine, August 23, 2021 Approval Letter Comirnaty, receiving your single-use Controlant shipment, Controlant Onsite Temperature Monitoring Playbook for Sites, Pfizer's Vaccine Formulation/Presentation Guide, CDC's Pfizer-BioNTech COVID-19 Vaccine Products At-A-Glance, FDA's Pfizer-BioNTech COVID-19 Vaccine Presentations Wall Chart, Pediatric COVID-19 Vaccine Dosing Quick Reference Guide, Children who Transition from a Younger to Older Age Group, Transporting vaccine for vaccination clinics held at satellite, temporary or off-site locations, recipients ages 6 months to 4 years and their caregivers, Beyond use-date (BUD) guidance and labels, recipients ages 5 to 11 years and their caregivers, recipients ages 12 years and older and their caregivers, Clinical Immunization Safety Assessment COVIDvax, Temperature excursions within the clinic or site, A complex COVID-19 vaccine safety question about an individual patient residing in the U.S. not readily addressed by CDC guidance. The site is secure. Thank you for taking the time to confirm your preferences. Use a local account to log in. The date of expiration always falls on the last day of the month. Email / Username. Step 2 Access your favorite topics in a personalized feed while you're on the go. While the elements present (other than the CDC seal) are the same as the standard CDC card, the format is different for each nonstandard card. Following a thorough safety review, the Centers for Disease Control and Prevention and the Food and Drug Administration have confidence that the Johnson & Johnson vaccine is safe and effective in preventing COVID-19 and recommend its use to prevent serious illness, hospitalization and death from COVID-19. Open 24/7. Do not use the Pfizer products beyond 18 months from manufacture date. The Centers for Disease Control and Prevention (CDC) together with federal agencies, vaccine providers, jurisdictions, and . Use Pfizer-BioNTech's expiration date tool at lotexpiry.cvdvaccine.com to determine the vaccine's expiration date. Pfizer and BioNTech host medical updates and immunization site training sessions for all health care providers on the proper use of the Pfizer BioNTech COVID-19 vaccines. No change was made to the vaccines formula. Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. Visit CDC-INFO. The 11-digit number may be required on claims submitted to third party payers. Administering COVID-19 vaccines in North Carolina requires first that a provider enrolls with the State. The improved data file format provides a standardized and consistent presentation of lot distribution information that can be automatically transferred and validated against FDAs Regulatory Management system, which tracks licensed FDA products and manufacturers. Original strain. Business owners can also consider outsourcing the process of evaluating vaccine and booster documentation using a vaccine passport app. You will be subject to the destination website's privacy policy when you follow the link. If your last COVID vaccine was before September 2022, youre due for an updated dose. The Pfizer-BioNTech vaccine label remains for individuals aged 6 months to 11years since the vaccine is authorized but not yet approved for these age groups. Provider Training Summary (Updated Nov. 21, 2021), COVID-19 Vaccine Ordering Guidance(Updated June 1, 2022), Become a COVID-19 Vaccine Provider - VFC Enrollment, Sample PediatricCOVID-19 Vaccination Declination Form. CDC has defined the scope of the CDC COVID-19 Vaccination Program in terms of how the USG-provided vaccines may be used in the program. CDC Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations, COVID-19 Vaccination Site Accessibility Checklist (English), COVID-19 Vaccination Site Accessibility Checklist (Spanish), All CDC Guidance on Vaccine Administration, Summary List of User Guides and Previously Recorded Training Sessions, Latest Vaccine Guidance and Information for Providers, How to View Vaccination Information - Provider. First time users should review FDA's Electronic Submission Gateway (ESG) User Guide that provides industry participants with information and guidance on how to use the FDA ESG. EMR and IIS vendors may need to add fields to the EMR to record the VIS document type and edition date. Home Data Catalog Developers Video Guides NC Department of Health and Human Services <>/Font<>/XObject<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group<>/Tabs/S/StructParents 0>> This placeholder date, which is far in the future, is intended to serve as a . 2 0 obj Administration fees may not be reimbursable by payers. Do not use the vaccine in this shipment until you have received the quality report from Controlant advising on further use. %%EOF These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. The VIS Lookup Table allows users to link the VIS Fully-Encoded Text String to the corresponding Global Document Type Identifier (GDTI). Many sites that receive direct shipments of COVID-19 vaccine for patients ages 12 years and older have not been properly deactivating the Digital Data Loggers (DDLs). As fake vaccine cards become a nationwide problem, it's crucial to know how to verify one. Search FDA Submit search. Signs and symptoms of anaphylaxis may include: Call emergency services if you develop or witness any serious symptoms that could be anallergic reactionafter vaccination. COVID-19 VACCINE LOT NUMBER AND EXPIRATION DATES. On April 7, 2022, FDA authorized an extension (PDF, 136 KB) for the shelf life of the refrigerated Janssen COVID-19 Vaccine, allowing the product to be stored at 2-8 degrees . Name: Pfizer-BioNTech Comirnaty COVID-19 vaccine, Manufacturer: BioNTech Manufacturing GmbH, Approved for: Primary series in individuals age 6 months and older or as a booster dose in individuals age 5 to 11 years as well as 16 years and older (Pfizer-BioNTech Comirnaty COVID-19 vaccine), As a bivalent booster dose (Pfizer-BioNTech Comirnaty Original and Omicron BA.4/BA.5 in individuals age 5 years and older, As a bivalent booster dose (Pfizer-BioNTech Comirnaty Original and Omicron BA.1 in individuals age 12 years and older, How it's given: Injection in muscle (usually the upper arm). After doses are ordered by states, shipments begin the . Accordingly, use of these products outside of those that have been approved and authorized by FDA (often referred to as off-label use) is not recommended. The vaccine is approved for people who are 6 months of age and older. The benefits must also outweigh any risks. If the temperature monitoring device is unable to connect with the cell network, please follow the steps below. These steps allow Points of Use (POUs) to ensure proper data connection through a manual data upload using your local internet network. When in doubt about the appearance of a nonstandard card, contact the vaccination site (or system issuing the card) directly to verify. 125 0 obj <> endobj Email CDC-INFO. Tracking COVID-19 vaccine distribution and administration activities requires collaboration between public and private information technology (IT) systems and integration of existing and newly developed IT systems. Given this information, providers should draw up doses from each vial using five one-inch needles/syringes and one 1.5-inch needle/syringe. For assistance, please reach out to support@controlant.com. is intended to assist manufacturers of vaccines and other biological products to electronically submit post marketing lot distribution data to FDA under 21 . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use0004A, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5 mL dosage; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, single dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; booster, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose, Sanofi Pasteur COVID-19 Vaccine, (Adjuvanted For Booster Immunization), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose.
The Following Is Not Available From Interpol,
Let's Just Say, I'm A Special Girl,
All Star Cheer Rankings 2021,
Purple Hulk Strain Info,
Houses To Hire For Weddings Central Coast,
Articles P